Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System

OBJECTIVES: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely used for the treatment of type 2 diabetes. In large trials, the GLP-1RAs liraglutide and semaglutide improved cardiovascular outcomes, but semaglutide was associated with an increased risk of retinopathy progression. We herei...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadini, Gian Paolo, Sarangdhar, Mayur, Avogaro, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Pathophysiology/Complications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808638/
https://www.ncbi.nlm.nih.gov/pubmed/29449951
http://dx.doi.org/10.1136/bmjdrc-2017-000475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808638/
https://www.ncbi.nlm.nih.gov/pubmed/29449951
http://dx.doi.org/10.1136/bmjdrc-2017-000475

Ejemplares similares